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Autonomic Nervous System Mediation of the Pancreatic 
Polypeptide Response to Insulin-Induced Hypoglycemia 
in Conscious Rats* 
PETER J. HAVEL, SUSAN J. PARRY, DONALD L. CURRY, JUDITH S. STERN, 
JONES 0. AKPAN, AND RONALD L. GINGERICH 
Department of Physiological Sciences, School of Veterinary Medicine and Department of Nutrition, 
University of California, Davis, California 95616; and Department of Pediatrics, Washington University 
School of Medicine, St. Louis, Missouri 63110 
ABSTRACT. To investigate the neural regulation of pan- 
creatic polypeptide (PP) secretion during hypoglycemia in the 
rat, insulin was administered to chronically cannulated rata, and 
plasma PP responses were compared between saline-treated 
animals and animals pretreated with a ganglionic blocking agent 
(hexamethonium), a muscarinic antagonist (atropine), combined 
a- and b-adrenergic receptor blockade (propranolol + tolaxo- 
line), or combined adrenergic blockade + atropine. PP was 
measured using a new RIA which selectively detects PP in rat 
nlasma. In control rats (n = 10). plasma PP increased from a 
baseline level of 30 f  3 pg/ml to 271 f  41 pg/ml during hypo- 
glycemia (plasma glucose = 29 f  2 mg/dl) (APP = +241 f  42 
DEM. P < 0.0005). demonstrating that in rats, as in other 
species, insulin-induced hypoglycemia is a potent stimulus for 
PP release. PP only increased by 31 f  10 pg/ml during similar 
hypoglycemia in 7 hexamethonium-treated rata (P < 0.01 us. 
control animals). Thus, at least 90% of the PP response to 
hypoglycemia is neurally mediated. The plasma PP response to 
hypoglycemia was +35 f  24 pg/ml in atropine-treated rata (P 
0.01 us. control rata), suggesting that approximately 65% of the 
PP response is mediated via muscarinic acetylcholine receptors 
on the islet F cell. The PP response to hypoglycemia in rats 
with combined adrenergic blockade (A = +166 f  32 pg/ml) was 
slightly, but not significantly smaller than that in control rata. 
The combination of combined blockade + atropine resulted in a 
PP response (A = +26 f  7 pg/ml) to hypoglycemia that was 
similar to that in hexamethonium-treated rats (P < 0.01 vs. 
control rata). These results suggest: 1) The PP response to 
hypoglycemia is predominately the result of muscarinic, cholii- 
ergic activation. 2) There is a minor adrenergic contribution to 
the response. 3) The plasma PP response may be useful as an 
index of autonomic neural input to the islet during hypoglyce- 
mia. (Endocrirwlogy 130: 22252229,1992) 
T HE SECRETION of the islet hormone, pancreatic polypeptide (PP), is extremely sensitive to activa- 
tion of vagal input to the pancreas. Electrical stimulation 
of the vagus nerves or the administration of cholinergic 
agonists potently stimulates PP secretion via an atro- 
pine-sensitive mechanism (l-4). Vagal control of PP 
release is also mediated by autonomic neurotransmission 
between pre- and postganglionic parasympathetic nerves 
because the ganglionic blocking agent, hexamethonium, 
abolishes the PP response to vagal nerve stimulation (3). 
It is thought that vagal, parasympathetic input to the 
pancreas is activated during central neuroglucopenia be- 
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cause plasma PP increases during glucopenic stress pro- 
duced by insulin-induced hypoglycemia (5) or by admin- 
istration of 2-deoxy-D-glucose (6), and this response is 
largely eliminated by vagotomy (7,8). 
The peripheral neural pathway and neurochemical 
mediators of glucopenia-induced PP secretion have been 
characterized in several species (see reviews in Refs. 9 
and 10). In humans, and in dogs, the PP response to 
neuroglucopenia is nearly eliminated by atropine, dem- 
onstrating that the response is almost entirely the result 
of muscarinic, cholinergic stimulation (4,5). In addition, 
since graded doses of acetylcholine or graded degrees of 
electrical vagal nerve stimulation produce proportional 
increases of PP secretion (5), it has been suggested that 
plasma PP levels may be used as a quantitative rather 
than simply as a qualitative index of parasympathetic 
input to the pancreas. Thus, measurements of plasma 
PP, and PP responses to neuroglucopenia, have been 
used by numerous investigators to assess the effective- 
ness of therapeutic vagotomy (ll), as a marker for auto- 
nomic neuropathy (12,13), and as an index of the para- 
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sympathetic input to both the endocrine and exocrine 
pancreas (6,14,X$. However, in experiments conducted 
in calves, electrical stimulation of sympathetic nerves 
increases plasma PP levels, and this increase is atten- 
uated by the administration of adrenergic antagonists 
(16). Therefore, plasma PP responses to neuroglucopenia 
may not be solely mediated by parasympathetic neural 
activation in all species, since neuroglucopenia is also 
known to produce sympathoadrenal activation (17, 18). 
Investigation into the regulation of PP secretion in 
rodents has been prevented by two major problems. First, 
rat PP differs from human, canine, bovine, and porcine 
PP by eight amino acids (19). Therefore, antisera that 
are effective for measuring PP in these species are not 
necessarily effective for measuring PP in rat plasma. 
Second, antisera directed against the C-terminal hexa- 
peptide of PP, which does not vary between rats and 
other species, have not proved useful because these anti- 
sera cross-react with neuropeptide-Y (NPY) and peptide- 
YY (PYY) which are homologous with rat PP at four of 
the six amino acid residues. Thus, the neural regulation 
of PP secretion, which has been well characterized in 
other species, has not been established in the rat. We 
have recently developed and validated a sensitive assay 
for rat PP which does not cross-react with NPY or PYY 
Cm 
Therefore, to determine whether plasma PP levels are 
increased during neuroglucopenia in conscious rats, 
plasma PP levels were measured before and during in- 
sulin-induced hypoglycemia. To test whether hypogly- 
cemia-induced PP release is neurally mediated, rats were 
pretreated with the ganglionic blocker, hexamethonium, 
which impairs neurotransmission across parasympa- 
thetic and sympathoadrenal nicotinic ganglia (21). To 
determine the respective contributions of muscarinic, 
cholinergic, or adrenergic receptor activation to hypogly- 
cemia-induced increases of plasma PP, atropine or a 
combination of (Y- and /3-adrenergic antagonists was ad- 
ministered before the induction of hypoglycemia. Finally, 
to determine the combined contribution of choline@ 
and adrenergic activation, another group of rats received 
both atropine and adrenergic blockers. 
Materials and Methods 
Animals and cannula implantation 
Adult male Sprague-Dawley rats (390-510 g, Bantin and 
Kingman, Fremont, CA) were used for these studies. Rats were 
individually housed and fed a stock diet (Ralston Purina) and 
water ad libitum. The light/dark cycle was 12 h on and 12 h 
off, with lights on at 0600 h. In order to access mixed venous 
blood, each animal had a silicon jugular cannula (id, 0.3 mm; 
od, 0.6 mm, American Scientific, McGraw Park, IL) implanted 
in the right atrium via the right jugular vein under pentobar- 
bital anesthesia (65-80 mg/kg ip). The cannula was attached 
to a 2 cm piece of 20 gauge, L-shaped stainless steel tubing and 
routed SC to the top of the head. The steel tube with the attached 
cannula was then fixed to the skull using three small steel 
screws and dental cement. The cannulas were flushed with 
heparinized saline (50 U/ml) and capped when not in use. After 
the cannula implantation, a minimum of 72 h was allowed for 
recovery before experiments were conducted. 
Hypoglycemia protocol 
All animals were fasted overnight (-18 h) before the exper- 
iments. Experiments were conducted between 1100 and 1600 
h. Either saline, hexamethonium bromide (10 mg/kg), or atro- 
pine methyl bromide (Sigma Chemical Co., St. Louis, MO) (10 
mg/kg) were administered iv. Atropine methyl bromide was 
used rather than atropine sulfate because atropine methyl 
bromide does not readily cross the blood-brain barrier (21), and 
thus should not impair central nervous system muscarinic, 
choline@ neurotransmission. A fourth group received a com- 
bination of a /3-adrenergic blocker, propranolol HCI (1 mg/kg), 
Inderal, Ayerst Laboratories, New York, NY) and an a-adre- 
nergic blocker, tolazoline HCl (10 mg/kg) (Priscoline, Ciba- 
Geigy, Summit, NJ). Lastly, both muscarinic (atropine) and 
combined adrenergic blockade (propranolol + tolazoline) were 
induced in a fifth group of rats. Fifteen minutes after the 
administration of autonomic blockers baseline samples were 
drawn from the jugular cannula. Then 1.0-2.0 U/kg of regular 
porcine insulin (Squibb-Novo Inc., Bagsvaerd, Denmark) was 
administered iv as a bolus. A second blood sample was drawn 
30 min after the insulin injection. After each blood sample was 
drawn, an equal volume of heparinized blood (20 U/ml) from 
donor rats was replaced via the jugular cannula. 
Assays and data analysis 
Blood samples for glucose and PP determination were placed 
in tubes containing EDTA. All samples were kept on ice until 
centrifugation (20 min at 4 C). The plasma was then decanted 
and frozen at -20 C until assayed. 
Plasma glucose was assayed by the glucose oxidase method 
with a glucose analyzer (Beckman Instruments, Fullerton, CA). 
Plasma immunoreactive PP was measured radioimmunolog- 
ically in unextracted plasma with a guinea pig-derived antisera. 
PP levels in rat plasma were determined by a RIA previously 
described (20). The procedure consists of a step-wise addition 
of antibody and a labeled ligand in a disequilibrium incubation. 
Guinea pig antirat-PP serum (100 ~1) obtained from Linco 
Research, Inc. (St. Louis, MO) and plasma samples (100 ~1) 
were incubated for 72 h. [lz51]rat-PP tracer (100 ~1) was then 
added, and the tubes were incubated an additional 24 h. The 
free “‘1 was separated from the bound lz51 by a second antibody 
precipitation method using goat anti-guinea pig immunoglob- 
ulin G serum and normal guinea pig serum carrier (20). PP 
concentrations in both standard and unknown samples were 
analyzed by counting the pellet in an automated y-counter 
(Apex, Micromedic Systems, Inc., Horsham, PA). The calcu- 
lations were performed with a data reduction system using log/ 
logit transformation. 
The changes of plasma glucose and PP were calculated by 
subtracting the 0 min baseline value from the 30 min value 
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after the injection of insulin. The data are expressed as mean 
-C SE. Statistical comparisons of means within a group were 
made with a paired t test. For statistical comparisons of means 
of different groups, analysis of variance was performed followed 
by Dunnett’s posttest. 
Results 
Plasma glucose before and after insulin injection 
In control rats (n = lo), baseline plasma glucose av- 
eraged 100 +- 3 mg/dl and fell to 29 rt 2 mg/dl 30 min 
after insulin administration (A = -71 f 2 mg/dl) (Fig. 
1). Neither the degree of hypoglycemia nor the glucose 
decrement produced by insulin differed significantly 
among the five groups of animals. For example, in the 
hexamethonium-treated rats, baseline plasma glucose 
was 97 f 3 mg/dl (n = 7) and decreased to 26 k 2 mg/ 
dl, 30 min after insulin injection (A = -71 f 4 mg/dl). 
Plasma PP before and during insulin-induced 
hypoglycemia 
Baseline plasma PP in control rats was 30 + 3 pg/ml. 
Plasma PP increased by more than 7-fold during insulin- 
induced hypoglycemia; to 271 f 41 pg/ml (A = +241 + 
42 pg/ml, P < 0.0005) (Fig. 2). Plasma PP in hexame- 
thonium-treated rats averaged 32 + 4 pg/ml before in- 
sulin injection. There was a small but significant increase 
of PP during hypoglycemia (A = +31 & 10 pg/ml, P < 
0.025). This response was significantly smaller than the 
response in control rats (P < 0.01). In atropine-treated 
rats, baseline PP averaged 27 k 2 pg/ml. In six out of 
seven atropinized animals the PP was 125 pg/ml, which 
is the level of detection for this assay. Plasma PP was 
increased significantly during hypoglycemia in atropin- 
ized rats; by +85 f 24 pg/ml (P < 0.01). However, this 
response was reduced by approximately 65% and was 
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FIG. 1. Plasma glucose levels before and after iv insulin injection in 
control, atropine-treated, hexamethonium-treated, propranolol + to- 
lazoline-treated, and propranolol + tolazoline + atropine-treated con- 
scious rats. 
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FIG. 2. Plasma PP levels before and during insulin-induced hypogly- 
cemia in control, atropine-treated, and hexamethonium-treated con- 
scious rats. 
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FIG. 3. Plasma PP levels before and during insulin-induced hypogly- 
cemia in control, propranolol + tolazoline-treated, and (propranolol + 
tolazoline) + atropine-treated conscious rats. 
significantly smaller than the response in control rats (P 
< 0.01). Plasma PP in rats treated with both (Y- and p- 
adrenergic antagonists increased from 51 + 8 pg/ml to 
219 f 31 pg/ml during hypoglycemia (A = +168 + 32 
pg/ml, P < 0.0025) (Fig. 3). In rats that received both 
atropine and combined adrenergic blockade, baseline 
plasma PP was 39 + 6 pg/ml and increased to 66 + 7 pg/ 
ml (A = +26 + 7 pg/ml, P < 0.005). This response was 
significantly reduced compared to that in the control rats 
(P < 0.01). 
Discussion 
In this study, we have demonstrated that plasma PP 
levels increase during hypoglycemia in conscious rats. 
To our knowledge, this is the first demonstration of 
increased PP release during central glucopenia in this 
species. Because PP was only measured at one time point 
during hypoglycemia, the glucose threshold for PP re- 
lease in the rat was not determined. This study was made 
possible by the development of an assay for PP in rat 
plasma which uses antiserum that is both sensitive and 
specific for rat PP (20). Earlier attempts to measure 
plasma PP in rats have utilized antisera directed against 
the C-terminal hexapeptide of PP (22, 23). The baseline 
levels of PP reported in these two studies were much 
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larger (>200 pg/ml) than in the present study (-30 pg/ 
ml). It is likely that these higher levels, in fact, represent 
a cross-reactivity with circulating neuropeptide-Y 
(NPY), which has significant homology with the C- 
terminal hexapeptide (19). Plasma NPY levels are known 
to be high in rats, and are thought to be derived from 
platelets (24). Measurements of PP levels with the hex- 
apeptide-directed antisera did not demonstrate a signif- 
icant increase of plasma PP during insulin-induced hy- 
poglycemia in rats (22, 23). However, these studies were 
performed in rats anesthetized with pentobarbital, an 
anesthetic which is known to markedly inhibit the PP 
response to central glucopenic stress (4, 6). 
Pretreatment with the nicotinic acetylcholine antago- 
nist hexamethonium, inhibited the PP response to in- 
sulin-induced hypoglycemia by nearly 90%, demonstrat- 
ing that the majority of the plasma PP response to 
insulin-induced hypoglycemia is neurally mediated and 
that nicotinic neurotransmission across autonomic gan- 
glia is involved in the neural pathway mediating the 
response. Hexamethonium has been demonstrated to 
inhibit the PP response to neuroglucopenia induced by 
2-deoxy-D-glucose in dogs (25). The small portion of the 
response not blocked by hexamethonium could poten- 
tially result from a direct effect of low glucose levels at 
F cell or to stimulation by unidentified humoral factors 
released during hypoglycemia. 
Pretreatment with atropine reduced the PP response 
by approximately 65% suggesting that, as in other species 
(4, 5), PP release during glucopenic stress is mediated, 
at least in part, by muscarinic acetylcholine receptors on 
the pancreatic F cell. However, in dogs and in humans, 
the PP response to neuroglucopenia is nearly abolished 
by atropine (4, 5) suggesting that potential species-re- 
lated differences are present in the amount of cholinergic 
contribution to the response. 
The PP response to insulin-induced hypoglycemia was 
smaller in rats treated with (Y- and /3-adrenergic antago- 
nists than in control rats, but this modest decrease did 
not achieve statistical significance. However, the addi- 
tion of combined adrenergic blockade to muscarinic 
blockade with atropine resulted in a plasma PP response 
that was equivalent to that in hexamethonium-treated 
animals. Thus, it appears that, in rats, the PP response 
to hypoglycemia may be partially mediated by adrenergic, 
in addition to cholinergic mechanisms. This result con- 
trasts with data obtained from experiments in other 
species in which the PP response to insulin-induced 
hypoglycemia is almost entirely the result of muscarinic, 
choline@ activation (4, 5). In humans, a-adrenergic 
agonism inhibits PP secretion and P-adrenergic agonism 
stimulates PP secretion (26). However, the dominant 
catecholamines in plasma, epinephrine and norepineph- 
rine, have little net effect on either basal (26, 27) or 
insulin hypoglycemia-induced PP release (28), perhaps 
because of the opposing (Y- and @-adrenergic effects of 
these mixed agonists. Although, the effects of adrenergic 
antagonists on the PP response to hypoglycemia have 
not been examined in other species, it has been previ- 
ously shown that electrical stimulation sympathetic 
(splanchnic) nerves increases plasma PP in calves, and 
this increase is attenuated by adrenergic antagonists 
(16). In addition, there is evidence for adrenergic regu- 
lation of PP secretion in avian species (29, 30). There- 
fore, in some species, there is potential for adrenergic 
mediation of PP secretion. 
In summary, we have demonstrated a neurally me- 
diated increase of plasma PP during insulin-induced 
hypoglycemia in the rat. Similar to other species, most 
of this increase is mediated by muscarinic acetylcholine 
receptors on the pancreatic F cell. However, in contrast 
to other species, a small portion of the PP response to 
hypoglycemia may be adrenergically mediated. Thus, the 
atropine-sensitive component of plasma PP levels and 
the plasma PP response to insulin-induced hypoglycemia 
may be useful as an index of the parasympathetic, cho- 
linergic input to the pancreas in rats provided that the 
potential for mediation by other factors is carefully con- 
sidered and investigated. 
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